Cargando…

Multi-omics fusion analysis models with machine learning predict survival of HER2-negative metastatic breast cancer: a multicenter prospective observational study

Detalles Bibliográficos
Autores principales:	Wang, Jiani, Liu, Yuwei, Zhang, Renzhi, Liu, Zhenyu, Yi, Zongbi, Guan, Xiuwen, Zhao, Xinming, Jiang, Jingying, Tian, Jie, Ma, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150865/ https://www.ncbi.nlm.nih.gov/pubmed/37027394 http://dx.doi.org/10.1097/CM9.0000000000002625

Ejemplares similares

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
por: Ma, Fei, et al.
Publicado: (2016)

Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer
por: Nakamura, Yoshiaki, et al.
Publicado: (2019)

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
por: Park, Yeon Hee, et al.
Publicado: (2023)

BnaOmics: A comprehensive platform combining pan-genome and multi-omics data from Brassica napus
por: Cui, Xiaobo, et al.
Publicado: (2023)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer
por: Mo, Hongnan, et al.
Publicado: (2020)

Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
por: Altundag, Kadri
Publicado: (2017)

Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study
por: Jiang, Mingxia, et al.
Publicado: (2023)

The Country Dai and Her Ministrations
por: Chakravarty, Tarak Nath
Publicado: (1927)

Teabase: A comprehensive omics database of Camellia
por: Li, Xuzhen, et al.
Publicado: (2023)

Partial treatment response to alectinib in metastatic non-small cell lung cancer with KIDINS220-ALK fusion
por: Lei, Yanna, et al.
Publicado: (2023)

The molecular tumor burden index as a response evaluation criterion in breast cancer
por: Yi, Zongbi, et al.
Publicado: (2021)

Reply to Tasker and to Lellouche and L’Her
por: Palmer, Edward, et al.
Publicado: (2020)

Data reproducibility issues on evidence synthesis of adverse events associated with HER2-targeted antibody–drug conjugates
por: Wu, Dan-Na, et al.
Publicado: (2023)

Response to crizotinib in a patient with metastatic lung spindle cell carcinoma harboring TPM3-ROS1 fusion
por: Cai, Cun-Liang, et al.
Publicado: (2019)

Home cryopreservation of fecal samples: an effective strategy for longitudinal studies using multi-omics approaches
por: Yan, Pengguang, et al.
Publicado: (2022)

EXPOsOMICS: final policy workshop and stakeholder consultation
por: Turner, Michelle C., et al.
Publicado: (2018)

Generation of patient-derived models from a metastatic pediatric diffuse leptomeningeal glioneuronal tumor with KIAA1549::BRAF fusion
por: Messiaen, Julie, et al.
Publicado: (2022)

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
por: Xia, Shuai, et al.
Publicado: (2020)

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
por: Guan, Xiuwen, et al.
Publicado: (2016)

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration
por: McShane, Lisa M, et al.
Publicado: (2013)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Current approaches to the management of Her2-negative metastatic breast cancer
por: Gogineni, Keerthi, et al.
Publicado: (2012)

Parotid Gland as Initial Metastatic Site of Nasopharyngeal Carcinoma
por: Wang, Yan, et al.
Publicado: (2016)

Space between the titanium plate of zero-profile cage and endplate of the vertebral body might affect the fusion process in anterior cervical discectomy and fusion
por: Deng, Yi-Fei, et al.
Publicado: (2020)

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
por: Yang, Jiao, et al.
Publicado: (2023)

The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study
por: Liu, Binliang, et al.
Publicado: (2018)

Contactless evaluation of rigidity in Parkinson's disease by machine vision and machine learning
por: Zhu, Xue, et al.
Publicado: (2023)

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

An integrated systems biology approach to the study of preterm birth using "-omic" technology - a guideline for research
por: Gracie, Sara, et al.
Publicado: (2011)

Integrated multi‐omics profiling of high‐grade estrogen receptor‐positive, HER2‐negative breast cancer
por: Wang, Kang, et al.
Publicado: (2021)

Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
por: Lorusso, Vito, et al.
Publicado: (2020)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3n6bntv2di2sfsmfe5nmsnap2i